KhalilMTeunissenCEOttoM, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol2018; 14(10): 577–589.
2.
GiovannoniG.Cerebrospinal fluid neurofilament: The biomarker that will resuscitate the ‘Spinal Tap’. Mult Scler2010; 16(3): 285–286.
3.
HutchinsonM.The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary. Mult Scler2015; 21(10): 1242–1243.
4.
KuhleJBarroCAndreassonU, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med2016; 54(10): 1655–1661.
5.
DisantoGBarroCBenkertP, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol2020; 26: 17–19.
6.
KuhleJKropshoferHHaeringDA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology2020; 26: 19–21.
7.
YaldizliÖBarroCMichalakM, et al. Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice. Mult Scler2018; 24(Suppl. 2): 97–98.
8.
SormaniMPHaeringDAKropshoferH, et al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann Clin Trans Neurol2019; 6: 1081–1089.
9.
AkgunKKretschmannNHaaseR, et al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol Neuroinflamm2019; 6(3): e555.
10.
DallaCostaGMartinelliVMoiolaL, et al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol2019; 85(4): 606–610.
